

Pengana High Conviction Equities Fund

Notice to Investors 1 April 2025

We write to provide an update on the recent developments concerning Opthea Limited (ASX: OPT) and advise that the Pengana High Conviction Equities Fund has been reopened for applications and redemptions.

As previously communicated, trading in the Fund was suspended following Opthea's announcement on 24 March 2025 that its COAST Phase 3 clinical trial did not meet its primary efficacy objective. This holding represented 5.8% of the Fund and created material uncertainty around valuation, prompting us to suspend unit pricing and fund flows in line with our duty to ensure fairness to all investors.

Opthea Update

Yesterday, following a review of the interim data from the second Phase 3 clinical trial (SHORE), which showed similar efficacy outcomes, Opthea announced that the company will no longer pursue development of a drug for wet age-related macular degeneration. Opthea is in active discussions with the financiers that funded the two Phase 3 studies regarding any potential claim they may have on the company's remaining cash reserves, and has commenced a process to significantly reduce operating costs while engaging with advisors on future options for the business.

Fund Reopening and Valuation Impact

With this clarity, we assess the revised value of Opthea to be in the range of 0 – 5 cents per share (off from 60 cents per share when the shares were suspended on the 17th of March) with a greater probability weighted to the low end of this range. We have accordingly assigned a value of 2 cents per share, recognising that small differences within this range will not have a material effect on total Fund valuation. This enables us to resume normal Fund operations, and the Fund has now been reopened to applications and redemptions.

Looking Ahead

While the Opthea outcome is a reminder of the inherent risks in early-stage healthcare investing, it does not alter our investment approach. The Fund has a strong track record in this area and continues to target companies with significant upside potential where value can be unlocked through catalysts such as regulatory approvals, business model inflections, or strategic re-ratings.

We thank you for your patience and support during this period and remain committed to transparent and timely communication.